Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
6 May 24
8-K
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
6 May 24
ARS
2023 FY
Annual report to shareholders
17 Apr 24
DEFA14A
Additional proxy soliciting materials
17 Apr 24
DEF 14A
Definitive proxy
17 Apr 24
S-8
Registration of securities for employees
20 Mar 24
10-K
2023 FY
Annual report
20 Mar 24
8-K
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
20 Mar 24
8-K
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of
5 Feb 24
8-K
Departure of Directors or Certain Officers
19 Dec 23
8-K
Other Events
14 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
8 Nov 23
8-K
Entry into a Material Definitive Agreement
1 Nov 23
8-K
Other Events
25 Oct 23
8-K
Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
7 Sep 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update
11 Aug 23
8-K
Entry into a Material Definitive Agreement
5 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
30 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update
10 May 23
DEFA14A
Additional proxy soliciting materials
11 Apr 23
DEF 14A
Definitive proxy
11 Apr 23
8-K
Other Events
5 Apr 23
S-8
Registration of securities for employees
22 Mar 23
10-K
2022 FY
Annual report
22 Mar 23
8-K
Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update
22 Mar 23
8-K
Entry into a Material Definitive Agreement
9 Jan 23
8-K
Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update
5 Jan 23
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
30 Dec 22
EFFECT
Notice of effectiveness
30 Dec 22
424B7
Prospectus with selling stockholder info
29 Dec 22
CORRESP
Correspondence with SEC
27 Dec 22
UPLOAD
Letter from SEC
22 Dec 22
S-3
Shelf registration
16 Dec 22
8-K
Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study
6 Dec 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
10 Nov 22
8-K
Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update
24 Oct 22
Latest ownership filings
4
Kate McKinley
22 Mar 24
4
Mir Hashim
22 Mar 24
4
Eric Groen
22 Mar 24
4
Talat Imran
22 Mar 24
4
Svai S Sanford
22 Mar 24
4
Svai S Sanford
19 Dec 23
4
Mir Hashim
19 Dec 23
4
Dennis A Ausiello
19 Dec 23
4
Talat Imran
19 Dec 23
4
JEAN LUC BUTEL
19 Dec 23
4
Eric Groen
19 Dec 23
4
Maulik Nanavaty
19 Dec 23
4
LAUREEN DEBUONO
19 Dec 23
4
Andrew Farquharson
19 Dec 23
4
Kate McKinley
19 Dec 23
4
Lisa Ann Rometty
19 Dec 23
4
MIR A IMRAN
19 Dec 23
SC 13D/A
South Lake One LLC
8 Dec 23
SC 13D/A
Quiroga Cortes Isidoro Alfonso
8 Dec 23
4
Cortes Isidoro Alfonso Quiroga
8 Dec 23
4
Change in insider ownership
8 Dec 23
4
Talat Imran
7 Dec 23
4
Talat Imran
6 Dec 23
4
Talat Imran
1 Dec 23
4
JEAN LUC BUTEL
21 Nov 23
4
Maulik Nanavaty
20 Nov 23
4
Talat Imran
9 Nov 23
4
Kate McKinley
8 Aug 23
3
Kate McKinley
8 Aug 23
4
MIR A IMRAN
30 May 23
4
Maulik Nanavaty
30 May 23
4
Lisa Ann Rometty
30 May 23
4
LAUREEN DEBUONO
30 May 23
4
JEAN LUC BUTEL
30 May 23
4
Dennis A Ausiello
30 May 23
4
Andrew Farquharson
30 May 23
4
Change in insider ownership
15 May 23
4
Change in insider ownership
10 May 23
4
Change in insider ownership
5 May 23
4
Change in insider ownership
2 May 23